The question yet to be settled, however, is the true duration of response, he added.
The study is sponsored by AstraZeneca. Dr. Hyman disclosed consulting for Atara Biotherapeutics. Dr. Soria reported having no disclosures.
News
Pan-AKT inhibitor shrinks tumors in patients with AKT1 mutation
Publish date: November 14, 2015